@xconomy.com 6 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 1 year ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 1 year ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com 1 year ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On